Jonathan S. Serody
Affiliations: | Microbiology & Immunology | University of North Carolina, Chapel Hill, Chapel Hill, NC |
Area:
Immunology, OncologyGoogle:
"Jonathan Serody"Children
Sign in to add trainee| Christian A. Wysocki | grad student | 2005 | UNC Chapel Hill |
| Joseph E. Burgents | grad student | 2010 | UNC Chapel Hill |
| Robert L. Mango | grad student | 2010 | UNC Chapel Hill |
| LeShara M. Fulton | grad student | 2013 | UNC Chapel Hill |
| Christof C. Smith | grad student | 2015-2020 | UNC Chapel Hill (Cancer Research Tree) |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Dong H, He X, Zhang L, et al. (2024) Targeting PRMT9-mediated arginine methylation suppresses cancer stem cell maintenance and elicits cGAS-mediated anticancer immunity. Nature Cancer |
| Vincent BG, File DM, McKinnon KP, et al. (2023) Efficacy of a Dual-Epitope Dendritic Cell Vaccine as Part of Combined Immunotherapy for HER2-Expressing Breast Tumors. Journal of Immunology (Baltimore, Md. : 1950) |
| Routh ED, Woodcock MG, Beckabir W, et al. (2023) Evaluation of tumor antigen-specific antibody responses in patients with metastatic triple negative breast cancer treated with cyclophosphamide and pembrolizumab. Journal For Immunotherapy of Cancer. 11 |
| Larson JH, Jin S, Loschi M, et al. (2023) Enforced gut homing of murine regulatory T cells reduces early graft-versus-host disease severity. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons |
| Zaiken MC, Flynn R, Paz KG, et al. (2022) BET-bromodomain and EZH2 inhibitor treated chronic GVHD mice have blunted germinal centers with distinct transcriptomes. Blood |
| Anders CK, Woodcock MG, Van Swearingen AED, et al. (2022) Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer. Journal For Immunotherapy of Cancer. 10 |
| Downs-Canner SM, Meier J, Vincent BG, et al. (2022) B Cell Function in the Tumor Microenvironment. Annual Review of Immunology |
| Zeidner JF, Vincent BG, Ivanova A, et al. (2021) Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. Blood Cancer Discovery. 2: 616-629 |
| Voorhees TJ, Zhao B, Oldan J, et al. (2021) Pretherapy metabolic tumor volume associates with response to CD30 CAR T cells in Hodgkin lymphoma. Blood Advances |
| Bruce DW, Kolupaev OV, Laurie SJ, et al. (2021) Third Party Type 2 Innate Lymphoid Cells Prevent and Treat GI Tract GvHD. Blood Advances |